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Abstract 
Ethanolic, methanolic and water extracts of different chemical phenotypes of Cannabis 
sativa belonging to the Cannabaceae family were tested for their antimicrobial activity 
against two Gram negative species, seven Gram positive species and two fungal species 
using the Kirby-Bauer disc diffusion method. Successful extracts were tested for their 
minimum inhibitory concentration (MIC). All extracts tested proved ineffective against 
both Gram negative species and both fungal species. Gram positive organisms were 
inhibited by all extracts, to varying degrees, and produced MICs of under 10 µl of extract 
per ml of inoculated broth. The average zones of inhibition (ZOI) produced for the 
successful species, when all extract inhibitions were combined, varied from 12.52 mm for 
Enterococcus faecium to 21.08 mm for Streptococcus pyogenes. The CBG (cannabigerol) 
type Cannabis extract proved the largest ZOI producer with results averaging 21.62 mm 
when all species’ inhibition was combined, and CBCV (cannabichromavarin) proved to 
produce the smallest ZOIs against all species with only an average of 7.29 mm. 
Synthetic cannabinoids that act on the same CB1 and CB2 receptors in animals were also 
tested for their antimicrobial activity. Ten in total were tested with one, 5F – PB -22, 
producing very slight inhibition against all Gram positive species except MRSA, and two 
more (5f – NPB – 22 and STS – 135) producing very slight inhibition against MRSA but no 
other species. 
Bactericidal testing was performed on all successful extracts and the results indicated that 
nearly all cannabinoids, against all species, are bacteriostatic. However, these results are 
thought to not be accurate as the method used could result in potential false positive 
results that show bacteriostatic activity. 
The results obtained in this study were corroborated by some of the studies undertaken 
by other researchers, but also contradicted by others. In total the amount of studies for 
comparison is very small and the results they produce are contradictory. The data 
indicates that Cannabis sativa has antimicrobial activities but the differing results from 
the studies performed so far show that experimental variation between the studies may 
influence the species upon which the cannabinoids are successful.  
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1 Introduction 
1.1 The History of Cannabis sativa 
Cannabis sativa is a plant in the Cannabaceae family that has been utilised for textiles and 
medicine by humans for thousands of years (Andre et al, 2016), starting in Asia prior to 
2400 BC (Jiang et al, 2006). Some of the earliest traces of humanity’s interaction with the 
Cannabis sativa were found in Japan where an archaeological site in the Oki Islands had 
Cannabis achenes from 8000 BC (Long et al, 2016) probably signifying use of the plant. 
There is evidence of Cannabis being present in Europe as early as the 12th century where 
Cannabis sativa was introduced by Muslims in paper manufacture techniques (Aldrich, 
1997). 
Cannabis was used by humans as a source of textiles, food and was also used for its 
psychoactive properties. Throughout the 1800s the use and cultivation of Cannabis was 
widespread across the globe but toward the latter end of the 19th century, many 
countries/states had criminalised its use, especially for slave workers in the likes of British 
Singapore and British Mauritius (Mauritian Government, 1867), Greece and several 
countries in the Islamic World. Cannabis began to re-attract attention medicinally in the 
1970s and 1980s in the USA, mainly due to its use by cancer and AIDS patients undergoing 
chemotherapy and wasting syndrome (Joy et al, 1999) and in 1996 California legalised 
medicinal Cannabis. In the last decade the world has begun to embrace Cannabis, with 
many countries and states now allowing Cannabis for medicinal and/or recreational use. 
This has greatly increased the availability of the plant for research into a potentially huge 
variety of medicinal applications. 
Cannabis can be separated into two varieties Cannabis sativa cultivated for its 
cannabinoids, mainly delta-9-tetrahydrocannabinol (THC), and Cannabis sativa grown as 
hemp with less than 0.2% THC but rich in fibre, oils and molecules (Andre et al, 2016). 
Hemp is widely grown around the world in countries where the psychoactive varieties are 
illegal. In the UK large amounts of hemp are processed for their cannabinoids and shipped 
across the globe, medicinal global sales also occur from the UK with a UN International 
Control Board finding 44.9% of the world’s Cannabis for medicinal and scientific use was 
produced in the UK. 
Now there is a rapidly growing industry emerging around the Cannabis sativa plant, with 
a projected global revenue of $31.4 billion by 2021 (Zhang, 2017) and 32.7% of Canadians 
 
 
aged between 15 and 64 having tried Cannabis in the year 2015/2016 according to the 
World Drug Report 2016 produced by the United Nations Office on Drugs and Crime. 
Some economies in some states have earned large sums of tax revenue, with Colorado 
alone generating $927,000,000 in tax revenue since 2014 from Marijuana taxes, licenses 
and fee revenues according to the Marijuana Tax Data (Colorado Department of Revenue, 
2019). 
 
1.2 Bioactive Compounds in Cannabis sativa 
Antibiotic resistance is becoming a widespread problem throughout the world and new 
antibiotics are desperately needed. Plants have been looked at for sources of natural 
antimicrobials for millennia. Fernandez et al (1996) found that the thionins found in 
barley and wheat were toxic to types of fungi, Gram positive and negative bacteria. 
Mendoza et al (1997) found terpenes isolated from the Pseudognaphalium genus showed 
antimicrobial properties. Terpenes, which are found abundantly in Cannabis sativa and 
other essential oil producing plants, have also been shown to have strong inhibition 
against Campylobacter spp. (Kurekci et al, 2013) and E. coli and S. aureus (Zengin and 
Baysal, 2014). Flavones and flavonols have been known to share properties with terpenes 
and cannabinoids and have been shown to present anti-inflammatory, anti-cancer and 
neuroprotective properties (Andre et al, 2010) 
The Cannabis sativa plant contains many of these compounds, with a wide variety of 
phenols, terpenes, flavonoids, flavonols and cannabinoids. Phenols have been shown to 
have a useful antimicrobial ability against Xylella fastidiosa (Maddox et al, 2010) and 
Lactobacillus plantarum, Staphylococcus aureus and Candida albicans, as well as other 
species (Cueva et al, 2010). 
Cannabis contains many aromatic compounds that contribute to its distinctive, yet 
variable smell. Some of these molecules are found to be antibiotic against some 
microorganisms and have a wide scope of health benefits. Limonene, or D-limonene, is a 
potent antioxidant and anti-inflammatory agent, it has been shown to reduce stress in 
mice subject to environmental stress (d’Alessio et al, 2014), it may also boost the immune 
system and studies have shown it has anti-cancer properties (Bodake et al, 2002). 
Myrcene, another aromatic compound found in Cannabis also shows anti-inflammatory 
properties, is thought to help prevent cancer and in a study performed on mice, myrcene 
increased sleep duration by around 2.6 times (do Vale et al, 2002). 
 
 
These compounds can be increased or decreased in their concentrations through 
selective breeding of the traits that are desired (De Meijer, 1994). This is beneficial to the 
medicinal industry as potentially adverse chemicals, for example: delta-9-
tetrahydrocannabinol (THC) which is psychoactive, can be bred out of future plants, while 
the beneficial compounds for a specific purpose can be enhanced. This is particularly 
important for childhood illnesses that cannabinoids may help with; a strain of Cannabis 
sativa was created specifically for a child with severe seizures, suffering hundreds a day. 
The Cannabis strain (named “Charlotte’s web” after the little girl who it was created to 
help), was selectively bred to have large cannabidiol (CBD) concentrations and very low 
levels of THC and it reduced the seizures in the child to only 2 to 3 times a month, with no 
adverse THC related side-effects reported (Young, 2013). This is even more impressive 
because conventional medicines were totally ineffective and the parents of the child had 
been told that the child would not live for much longer, the CBD saved the child’s life. 
 
1.3 Cannabinoids and their synthesis 
Cannabinoids are a class of secondary products in the Cannabis sativa plant, they are 
terpenophenolic substances produced in the glandular trichomes of the plant (Hammond 
and Mahlberg, 1997).  
The biosynthetic pathways of phytocannabinoids have only recently been fully 
uncovered. Cannabigerolic acid (CBGA), the central precursor for several cannabinoids is 
synthesised by the alkylation of olivetolic acid (OLA), an alkylresorcinolic acid that forms 
the polyketide nucleus of the cannabinoids (Gagne et al, 2012) with Geranyl Diphosphate 
(GPP) via the enzyme geranylpyrophosphate:olivetolate geranyltransferase (GOP) 
(Fellermeier and Zenk, 1998). Three oxidocyclases are then responsible for differentiation 
into other cannabinoids: THC synthase, CBD (cannabidiol) synthase and CBC 
(cannabichromene) synthase all convert CBGA to THCA, CBDA & CBCA respectively (Taura 
et al, 2007; Sirikantaramas et al, 2004). THCA is the acid form of THC, a carboxylic acid 
group breaks off from the acid form when it is heated and becomes THC. This means that 
all Cannabis extracts used in the study will have contained a large proportion of the acid 
forms as they were only heated to 37 ˚C during the study, and 70 ˚C for one set of water 
extracts. 
 
 
Through analysis over the decades, many sub types and variations of cannabinoids have 
been found. Figure 1 shows the 4 main cannabinoid types, the R groups can be one of 
several variations that determine the exact sub-type of cannabinoid.  
The molecular layout and formulae of the cannabinoids and other compounds within 
Cannabis sativa have been known for a long time. T. Wood (1898) was the first to isolate 
a compound from Cannabis sativa, isolating Cannabinol. The next cannabinoid to be 
isolated was Cannabidiol (CBD) by Mechoulam and Shvo (1963) and then delta-9-
tetrahydrocannabinol was isolated by Gaoni and Mechoulam (1964). 
Our knowledge of the biosynthesis of main type cannabinoids has become so detailed 
that experiments have been performed that resulted in the production of a wide variety 
of cannabinoids by heterologous host organisms (Carvalho et al, 2017). Another by Luo et 
al (2019) showed that Saccharomyces cerevisiae could be engineered to completely 
synthesise several major cannabinoids, including THC, CBG and CBD. With more 
understanding of the synthetic pathways of rare cannabinoids, they too could be grown in 
microorganism species much more easily and then researched to discover any possible 
health benefits they may possess. These applications could also be applied to the plants 
themselves with advances in CRISPR (clustered regularly interspaced short palindromic 
repeats) technology. Research should be performed trying to manipulate normal 
Cannabis tissue (not just the trichomes) into synthesising a large volume of cannabinoids, 
massively increasing the yields of the plants. 
Figure 1. The 4 
main types of 
cannabinoids. 
1 – CBG type, 
2 – CBC type, 
3 – CBD type 
& 4 – THC 
type.  
Derived from 
ElSohly and 
Slade (2005).  
 
 
A study by Ross and ElSohly (1996) reported 483 individual natural compounds inside C. 
sativa L. Knowledge of the structures of antimicrobials is important in the field of 
antimicrobials, because if a compound is inhibitory of microorganisms then it will be due 
to its particular molecular structure and its subsequent effects. Knowing exactly which 
structures are effective against microorganisms will make synthesising antimicrobial 
molecules much easier in the future. 
Synthetic cannabinoids are manmade variants of cannabinoids which bind to CB1 and CB2 
receptors in humans and animals. However, toxicity and hospital admissions are much 
higher for synthetic cannabinoids than their natural counterparts, this is thought to be 
due to synthetic cannabinoids being direct agonists of the cannabinoid receptors, 
whereas THC is only a partial agonist (Mills et al, 2015). 
 
1.4 Medicinal uses of Cannabis sativa to date 
The medicinal activities of Cannabis sativa are broad, particularly in regard to the 
cannabinoids they produce. They have been shown to alleviate nausea symptoms and 
increase appetite in chemotherapy patients. Machado Rocha et al (2008) performed a 
meta-analysis study that found Dronabinol (an oily resin containing THC) had better acute 
anti‐emetic efficacy than conventional anti-emetic drugs. It has also been used for 
decades by many HIV/AIDS patients to alleviate nausea symptoms and help improve 
quality of life, however as of 2013, current studies suffer from effects of bias, small 
sample size, and lack of long-term data (Lutge et al, 2013). De Petrocellis et al (2011) 
found THC to be a potent anti-inflammatory, anti-cancer, analgesic, muscle relaxant and 
neuro-antioxidative. 
Cannabidiol has been shown to have beneficial effects comparable to clozapine, an 
atypical antipsychotic drug in a study performed by Gomez et al (2014) 
As early as 1888 it was reported that ‘indian hemp’ resulted in benefits on a Parkinsonian 
syndrome (Gowers, 1888; Russo, 2007). Further research has shown 22/28 Parkinson’s 
disease patients tolerated smoking Cannabis and benefitted from acute improvements in 
bradykinesia and tremors (Lotan et al, 2014). CBD has been shown to be a very promising 
molecule in neurodegenerative diseases, schizophrenia, multiple sclerosis and epilepsy 
(Hill et al, 2012) 
Chong et al (2006) found that 68% of multiple sclerosis patients questioned had used 
Cannabis to alleviate symptoms of multiple sclerosis and Chen et al (2019) found that 
 
 
Epidolex (Cannabidiol (CBD)) significantly reduces seizures in combination with standard 
antiepileptic therapies in infants less than 2 years old with Dravet and Lennox Gastaut 
syndromes. Cannabis is also thought to possess potential anti-cancer properties. 
Pokrywka et al (2016) showed that, in animal models and cell lines in vitro, that 
phytocannabinoids, endocannabinoids, synthetic cannabinoids and their analogues can 
lead to inhibition of the growth of many tumour types. Another study performed by 
Leanza (2016) showed that intraperitoneal applications of 5mg/kg of bodyweight CBD in 
nude mice every 3 days for 28 weeks resulted in almost completely reduced development 
of metastatic nodules caused by the injection of human lung carcinoma A549 cells. It can 
also be a powerful antimicrobial (Wasim et al, 1995). 
Studies have been performed that show that CBC presents antibacterial and antifungal 
ability (Eisohly et al, 1982) and sedative and analgesic properties (Davis and Hatoum, 
1983). 
Tetrahydrocannabivarin (THCV) has been shown to restore insulin signalling in insulin-
resistant hepatocytes and myotubes, as well as improving glucose tolerance and 
increased insulin sensitivity in genetically obese mice (Wargent et al, 2013). 
 
1.5 Detrimental health effects of Cannabis sativa 
While Cannabis sativa has myriad health benefits, there are studies highlighting potential 
dangers of Cannabis use. It possesses antimicrobial activity but a review by Elsohly (2007) 
showed that smoking of Cannabis can impair lung immune functionality, thus increasing 
susceptibility to bacterial lung infections by inhibiting alveolar macrophages’ nitric oxide 
production, causing immunosuppression (Roth et al, 2004). 
In the 1970s it was found that a combination of lipopolysaccharide (obtained from E. coli 
and 3 species of the genus Salmonella, S. Minnesota, S. typhi and S. abortus), THC and a 
commercial Pseudomonas vaccine proved to be highly toxic in mice (Bradley et al, 1977) 
and that this enhanced toxicity could arise in humans as humans have pathogenic, food-
borne, and enteric bacteria that can produce lipopolysaccharides.  
It has long been argued that Cannabis use, like cigarettes, can cause lung cancer and 
other pulmonary diseases such as emphysema. A survey at a large health maintenance 
organisation found that marijuana users were more likely to seek help for a variety of 
respiratory illnesses (Polen et al,1993). However, it also found that users who had 
consumed Cannabis for more than 10 years visited no more frequently than those who 
 
 
had smoked Cannabis for less than 10 years. Jett et al (2018) reviewed Cannabis use and 
the data behind its relationship with lung cancer, their studies found that smoking 
cannabis has so far not been definitively proved to be a risk factor in the development of 
lung cancer. The data, however, are limited by small studies, misclassification due to self-
reporting of use, small numbers of heavy cannabis smokers, and confounding of the risk 
associated with other factors like using Cannabis alongside chronic tobacco use. 
Cannabis has an age restriction in countries where it is recreationally legal because 
research has shown its detrimental effects on those who smoke at an early age. Studies 
have shown that those who smoked Cannabis during adolescence had fewer neural fibres 
in specific brain regions, including the precuneus, involved in functions requiring a high 
degree of integration such as self-conscious awareness and alertness, and the fimbria, 
located in the hippocampus that is used in learning and memory (Zalesky et al, 2012). A 
reduction in functional connectivity, responsible for executive function (including 
inhibitory control) and subcortical networks which are thought to process routines and 
habits, was also reported in a study by Filbey and Yezhuvath (2013). 
There is also a link between Cannabis sativa use and an increased risk of mental illness, 
including anxiety and depression, but causality is hard to establish because factors other 
than Cannabis may be directly associated with the risk of mental illness. However, studies 
have shown that Cannabis use correlates with an increased risk of mental illness (Patton, 
2002) especially amongst people with pre-existing genetic vulnerability to mental illness 
(Caspi et al, 2005). 
 
1.6 Antimicrobial properties of Cannabis sativa 
Cannabinoids have shown antimicrobial activity against a variety of different species, 
notably it has shown high activity against a variety of clinically relevant strains of MRSA 
(Appendino et al, 2008). Two particularly effective antimicrobial cannabinoids are 
Cannabichromene (CBC) and Cannabigerol (CBG) with CBG being a more potent 
antibacterial and CBC being a better antifungal agent. 
Ali et al (2011) found that the petroleum ether of the seeds, whole plant methanol 
extract and the oil of Cannabis sativa seeds, all produced inhibition against a small range 
of microorganisms. 
 
 
As of yet, there has been little study into the potential antimicrobial properties of 
synthetic cannabinoids. Also, very little is known about the impact of cannabinoids on 
virulence properties of bacteria.  
 
1.7 Aims for the Experiment 
1. Preparation of ethanol, methylated spirit and water extracts from dry tissues of 
different chemotypes of Cannabis sativa provided by Dr. E. De Meijer (GW 
Pharmaceuticals, Kent). The extractions will be done at 37 °C.  
2. Testing antimicrobial activities of the extracts against a range of microorganisms 
including: Bacillus cereus, Enterococcus faecium, Escherichia coli, Pseudomonas 
aeruginosa, Staphylococcus aureus (including MRSA), Staphylococcus epidermidis, 
Streptococcus pneumoniae, Streptococcus pyogenes, Candida albicans & Candida 
glabrata.  
This will be achieved by:  
a) measuring zones of inhibition (ZOI) of microbial growth in Kirby-Bauer disc diffusion 
assays, and  
b) determining minimum inhibitory concentrations (MIC) using serial dilutions of the 
extracts at constant concentrations of the microorganisms grown in liquid media in 96-
well plates. 
3. Looking at possible interactions between different cannabinoids by testing levels of 
their antimicrobial activities (by measuring ZOI) after mixing different extracts. If features 
of synergy, antagonism or addictiveness will take place, those effects will be verified by 
measuring MIC of the mixes.  
4. Checking whether any discovered antimicrobial effects are bacterio/fungicidal or 
bacterio/fungistatic (based on viability assays after growth inhibition).  
5. Any effects discovered for objectives 1-3 will be verified by using pure synthetic 
cannabinoids for CBC, CBD, CBG & THC, CBCV (cannabichromavarin), CBDV 
(cannabidavarin), CBGV (cannabigerovarin) & THCV. Dr. O. Sutcliffe agreed to supervise 
this part of the work. The synthetic cannabinoids tested were: 5F-NPB-22, 5F-PB-22, AB-
FUBINACA, AB-PINACA, BB-22, EG-018, MDMB-CHMICA, MDMB-CHMCZCA, STS-135 & 
THJ-018. 
 
 
6. Investigating effects of the extracts on the expression of pykA and argF genes (which 
encode the most important virulent proteins in MRSA).  
The research planned in this study will focus on non-antibiotic resistant strains (except 
MRSA) as the laboratory cannot accommodate many of those organisms, but they can still 
be pathogenic, especially in immunocompromised individuals. Cannabinoid extracts will 
be used to produce inhibition, with extracts being individual or combined in pairs to 
compare inhibition. Synthetic cannabinoids will also be tested to determine if they 
produce any antimicrobial results. If the cannabinoids prove successful, it would be 
interesting to apply them to antibiotic-resistant strains in the future. Attempts will also be 
made to initiate studying the effect of cannabinoids on the expression of genes (in 
particular argF & pykA) encoding important virulence proteins in MRSA. 
 
 
2 Methodology 
All tests were performed in triplicate using the same method, equipment and materials. 
2.1 Agar and Broth preparations 
Nutrient Agar / Broth (OXOID – CM0003 / CM0001) was used for all species except for: E. 
faecium, S. pneumoniae and S. pyogenes which were grown on Brain Heart Infusion Agar / 
Broth (OXOID – CM1136 / CM1135), and C. albicans and C. glabrata which were grown on 
Sabouraud Dextrose Agar (OXOID – CM0041). 500 ml of purified water was added to the 
required amount of agar or broth, as per the container’s instructions, and autoclaved at 
121 °C for 20 minutes. Agar plates were poured in a sterile flow cabinet using 
approximately 25 ml of agar per plate and allowed to set before storage and/or use. 
 
2.2 Preparations of agar and broth cultures for testing 
For agar plates approximately 2-3 ml of a saline solution, made up of a saline tablet 
dissolved in 500 ml of purified water, was mixed with a species and scanned in a 
spectrophotometer (Jenway 6305 spectrophotometer) at 600 nm, that had been 
calibrated with a saline solution blank, until an Optical Density (OD600) of around 0.3 was 
achieved, this indicates approximately 106 cfu (colony forming units) per ml. A sterile 
swab was then submerged in the saline–bacteria solution and streaked evenly across the 
agar three times, rotating after each streak to ensure even coverage. 
 
 
For the 96 well plate testing broth was used in place of saline for spectrophotometry. 
When an OD600 of around 0.3 was achieved the culture was added to the 96 well plate. 
 
 
2.3 Extract preparations 
150 mg of Cannabis sativa raw material was added to 1350 mg of solvent. Two water 
extracts and a methylated spirit extract were made using the most effective cannabinoid, 
CBG. Ethanol extracts used for the majority of the experiment were made for all 
cannabinoids. The extracts were vortexed and then incubated for 24 hours at 37 °C, one 
water extract was heated for 2 hours at 70 °C before being incubated at 37 °C for 22 
hours. After incubation all of the extracts were centrifuged at 1.7x1000g for 12 minutes, 
twice. The supernatant was then pipetted out and stored in 2 ml Eppendorf tubes; 
ethanol and methylated spirit extracts were stored in a freezer; water extracts were 
stored in a refrigerator. 
Combined extracts were performed by pipetting an equal volume of each Cannabis 
extract into an Eppendorf tube and vortexed for several seconds before use. 
One set of extracts were made using a 1:1 ratio of ethanol and Cannabis, by weight, for 
testing against Gram negative and fungi species. All solvents were left to evaporate from 
the extracts before being utilised in the study. 
 
2.4 Testing for antimicrobial activity (Kirby-Bauer disc diffusion method) 
Approximately 2 ml of saline solution was inoculated with a microorganism until an OD600 
value of around 0.3 was obtained. Then a sterile swab, having been submerged fully in 
the saline solution, was streaked across an agar plate from top to bottom. The plate was 
rotated and re-streaked twice more to ensure full plate coverage. 
Blank antibiotic discs were loaded with 15 microlitres of extract and left until the solvent 
had evaporated, either in a fume cupboard or near a Bunsen burner, then they were 
placed onto the agar and incubated at 37 °C for 24 hours. Both Streptococcus species 
were incubated at 37 °C with 5% CO2 and with slight humidity.  
 
 
 
 
2.5 Testing for antimicrobial activity (MIC 96 well plate assays)  
96 well plates were used, with lane 1 containing 90 µl of double concentration broth, 45 
µl of extract and 45 µl of water. Lanes 2-10 had 150 µl of broth inoculated with a species 
(with an OD600 of 0.3, diluted 500x). Lanes 11 and 12 were filled only with 150 µl of broth. 
150 µl from lane 1 was transferred to lane 2 with a multi-channel pipette, resuspended 3 
times and then 150 µl transferred to the next lane, etc. Lane 10 did not have any extract 
added to it. Instead lane 9 had 150 µl removed, and disposed of, to create the same 
volume as all other wells. This resulted in their being half as much extract in each 
consecutive lane. Lane 2 contained 22.5 µl of extract in a total volume of 150 µl, lane 3 
contained 11.25 µl, lane 4 contained 5.625 µl, etc. 
Each row contained a separate extract corresponding with its numerical equivalent, with 
Row A containing extract 1, Row B containing extract 2 (CBC), etc. 
 96 well plates were scanned at 0 hours, T=0, using 500nm and 600nm wavelengths and 
then incubated at 37 °C, with both Streptococcus species being incubated at 37 °C with 
5% CO2 with slight humidity, the 96 well plates were then scanned at T=24 and T=48.  
 
2.6 Testing for combined extract properties 
Each main cannabinoid type’s extract was combined with its ‘-Varin’ counterpart in a 1:1 
ratio by volume: CBC & CBCV, CBD & CBDV, CBG & CBGV and THC & THCV). Also, a set of 
extracts were made using the following pairs: CBCV & THCV, CBC & THC, CBDV & CBGV 
and CBD & CBG, in the same 1:1 ratio. These were then applied to blank antibiotic discs, 
dried in a fume cupboard or in close proximity to a Bunsen burner and then applied to an 
agar plate evenly streaked with a microorganism to determine inhibition. Once applied 
the completed agar was incubated at 37 °C for 24 hours. Both Streptococcus species were 
incubated at 37 °C with 5% CO2 and with slight humidity. 
 
2.7 Bacteriostatic/bactericidal testing 
After successful inhibition was produced by an extract, a sterile swab, or sterile toothpick 
(if the ZOI was very small), was applied to the ZOI and then transferred to a fresh agar 
plate. A Line was drawn across the plate with the swab/toothpick and the plate was then 
incubated overnight at 37 °C for 24 hours (both Streptococcus species were incubated at 
37 °C with 5% CO2 and with slight humidity) to determine if growth would occur or not. 
 
 
 
2.8 Synthetic cannabinoid testing 
Synthetic cannabinoids provided by Dr O. Sutcliffe were used, using the Kirby-Bauer disc 
diffusion method. Approximately 10 mg of synthetic cannabinoid was stored in a glass 
bijou and dissolved in 10 ml of dimethyl sulfoxide (DMSO), per 10 mg synthetic 
cannabinoid. 10 µl of which was then added to a blank antibiotic disc and placed on 
inoculated agar and incubated at 37 °C. Both Streptococcus species were incubated at 37 
°C with 5% CO2 with slight humidity. 
 
2.9 Measuring antimicrobial activity 
For the Kirby-Bauer disk diffusion method photographs were taken of all plates, after 
incubation, on a black tile alongside two perpendicular rulers. The photographs were then 
used to measure the ZOI, using a pair of dividers the diameter was measured and 
compared against the ruler. Extracts with very little antimicrobial activity produce values 
of 6.5+ mm due to the disc being 6 mm in diameter. 
The 96 well plates were scanned in a 96 well plate spectrophotometer at 500 and 600 nm 
absorbencies at T=0, T=24 and T=48. Photographs were taken of the plates at each 
incubation stage, the MIC was determined by identifying the volume of extract needed to 
halt bacterial growth after 24 or 48 hours. 
 
2.10 Aseptic technique: 
All research was performed within close proximity to one or more Bunsen burners or in a 
flow cabinet to try to ensure a sterile environment and reduce contamination risks. 
All glassware and relevant material such as antibiotic discs, pipette tips and solutions like 
water and saline were autoclaved before use to ensure sterility and reduce the chance of 
contamination. 
 
2.11 Statistical analysis 
Standard deviation was calculated to determine how consistent any results were, and T-
tests were performed between similar results to determine if there is any significant 
difference between the values. 
 
 
3 Results 
Candida albicans, Candida glabrata, Escherichia coli, and Psuedomonas aeruginosa all 
were uninhibited by all extracts tested. Therefore, they were excluded from tables to save 
space. 
Figure 2 shows each of the species listed above after incubation with all Cannabis 
extracts. No inhibition was produced in all plates. 
 
 
3.1 Solvent testing against MRSA using CBG 
Table 1 shows the results of each solvent type against MRSA using the cannabigerol 
extract and shows that methylated spirit extracts were slightly better inhibitors of MRSA 
than ethanol extracts with a 2-3% ZOI diameter increase for volumes 30, 45 and 60 µl. The 
water extracts produced smaller inhibition, only achieving 2/3rds the inhibition of 
Figure 2. C. glabrata (top left), C. albicans (top right), P. aeruginosa (bottom left) and 
E. coli (bottom right) plates showing that no inhibition occurred from any extract 
used. Each disc contained 15 µl of an extract. The top disc contains extract 1. With 
extracts 2, 4, 5, 6, 7, 8 and 9 in an anticlockwise direction. 
 
 
methylated spirit at 60 µl. Water extracts that were incubated at 70 °C for 2 hours, and 
then 22 hours at 37 °C, produced slightly smaller ZOIs than water extracts incubated 
solely at 37 °C for 24 hours.  
All extracts produced inhibition within 1 standard deviation of the mean except for the 15 
µl water extracts incubated at 70 °C for 2 hours and then 22 hours at 37 °C which was 
slightly more varied. 
Figure 3 shows the results of each solvent tested, with ethanol, methylated spirit and 
both of the water extracts. It clearly shows the distinct difference in ZOI produced, 
especially between the water extracts and the non-water extracts. This is represented in 
Graph 1, showing the smooth curves for all 4 solvents at each volume. 
 
 
 
Figure 3. A comparison of MRSA plates with different solvent CBG extracts tested; ethanol 
(top left), methylated spirit (top right), water extract at 37 degrees (bottom left) and finally 
water extracts incubated for 2 hours at 70 degrees. The discs, from top anticlockwise, contain 
15, 30, 45 and then 60 µl of extract.  
 
Graph 1. A comparison of the average ZOIs for each solvent tested using CBG against MRSA. 
MS – Methylated spirit. W 70 – Water incubated for 2 hours at 70 °C, then 37 °C for 22 
hours. E – Ethanol. W – Water incubated at 37 °C. 
 
 
3.2 Ethanol extracts against all species 
Table 2 contains the inhibition sizes of all extracts, at 15 µl, against all successfully 
inhibited species and Graph 2 shows the average ZOI for each extract against each 
species. Extracts 1 (CBCV) and 2 (CBC) proved to be the least effective cannabinoids with 
average ZOIs of only 6-8 mm for all species except Streptococcus pyogenes which had 
slightly better inhibition, 10.67 mm and 11.67 mm for CBCV and CBC respectively.  
Figure 4 shows two plates containing S. pyogenes and S. aureus and shows the difference 
in inhibitions between the two. CBCV was loaded on the disc at the top, the other extracts 
were loaded in numerical order counter clockwise from the top. 
 
The THC type Cannabis extracts provided moderate antimicrobial ability against all 
species with extract 4 (THCV) being worse against all species than its analogue extract 6 
(THC). THCV proved least effective against E. faecium with only a mean inhibition of 11.67 
mm, S. pneumoniae was the next most resistant with a mean inhibition of only 12 mm. 
Counterintuitively, S. pyogenes was the least resistant to the THCV extract as it produced 
an average ZOI of 23.33 mm. Figure 5 shows a comparison of an S. pneumoniae and S. 
pyogenes plate, highlighting the differences in ZOIs. Extracts 4 and 6 (left most and 
Figure 4. A comparison of an S. pyogenes plate (left) and an S. aureus plate (right). Discs 
contain 15 µl of extract, extract 1 is on the disc at the top. With extracts 2, 4, 5, 6, 7, 8 
and 9 in an anticlockwise direction. Extract 9 produced the largest ZOI for both species. 
 
 
bottom most discs), like most of the different extracts, have a noticeable difference in 
size. 
THC extracts proved a far better inhibitor of E. faecium, producing a mean ZOI 146% 
larger than THCV. Figure 6 shows a plate of E. faecium displaying the difference between 
THCV, 3rd disc anticlockwise from the top, and THC, the 5th disc. Extract 6 was the second 
strongest inhibitor against B. cereus, E. faecium, S. aureus, S. epidermidis, S. pneumoniae 
and S. pyogenes. 
 
Figure 5. Two plates comparing the inhibition zone sizes of each 15 µl extract against S. 
pneumoniae (left) and S. pyogenes (right). The top most disc contains extract 1, with extracts 
2, 4, 5, 6, 7, 8 and 9 in an anticlockwise direction.  
Figure 6. An E. faecium plate showing each 15 µl extract’s inhibition. The discs follow the same 
layout as described in Figures 4 and 5. 
 
 
 The most potent extract was extract 9 (CBG) with the strongest inhibition against all 
species except B. cereus with only a 16 mm average ZOI. The inhibition from CBG ranged 
from 17.33 mm, against E. faecium, to an impressive 28.33 mm, against S. pyogenes.  
Extract 8 on the other hand produced, generally, far less inhibitory results than its 
analogue, CBGV. When compared to extract 9 the results varied from 60% of the mean 
ZOI, against E. faecium, to 96%, against MRSA. The average zone size of CBGV produced 
83% the average ZOI of its analogue. The largest inhibitions produced by extract 8 were 
against MRSA, being only 1 mm less than the strongest extract and 0.33 mm less than 
extract 7 (CBD), however, extract 7 produced a more varied set of results with a standard 
deviation being 1.25 whereas CBGV produced very consistent zones of 24 mm. E. faecium 
and B. cereus were the least inhibited by extract 8, producing smaller inhibitions of 10.33 
mm and 12.33 mm. Figure 7 shows the very small inhibition of CBGV against B. cereus and 
E. faecium, the right hand most disc. However, it still produced more inhibition than 
extracts 1 and 2, central top and top left, respectively. 
The CBD type Cannabis extracts CBDV and CBD, extracts 5 and 7 respectively, produced 
successful inhibition. Extract 5 resulted in smaller inhibition zones than extract 7 against 
all species, with inhibition zones on average 82% the size of extract 7. The largest 
inhibition produced by extract 5 was against S. pyogenes with a mean ZOI of 22 mm 
however a standard deviation of 2.16 is far higher than all other results and one value of 
25 mm raises the average. The smallest inhibition zones were produced against S. 
pneumoniae with only 10.67 mm average ZOI. Extract 7 produced quite strong activity 
Figure 7. A comparison of B. cereus and E. faecium plates tested with 15 µl of each extract. 
The discs follow the same layout as described in Figures 4 and 5.  
 
 
against all species, with large inhibitions of 24.33 mm and 25 mm against MRSA and S. 
pyogenes. It produced the least inhibition against S. pneumoniae and E. faecium with only 
14.67 mm and 16.33 mm on average. 
 
 
 
 
 
 
 
 
 
 
 
Tables 3 and 4 show the average inhibition against each species when all extract ZOIs 
(using 15 µl) were combined, and the average inhibition of each cannabinoid extract 
(using 15 µl) against all species, respectively. This shows extract 9 (CBG) had the highest 
average inhibition against all species, at 21.62 mm, and extract 1 (CBCV) produced the 
lowest with 7.29 mm. Table 3 shows that S. pyogenes was the most inhibited species 
when taking into account all cannabinoid extracts ZOIs and that E. faecium was the most 
resistant to the Cannabis extract’s inhibition.  
 
3.3 MIC 96 well plate testing 
The species in Table 2 were tested with serial dilutions of the extracts to determine MICs. 
96 well plates were scanned with a spectrophotometer at 600 nm and photographed. 
MICs were determined visually and via the readings from the spectrophotometer, 
Figure 8 shows the readings from an MRSA 96 well plate, after being incubated for 48 
hours, with emphasis being drawn to squares A6, A7, B6 and B7 showing the sudden 
increases in absorbance between the adjacent wells. This shows that for CBCV and CBC 
extracts the MIC was the 6th lane with approximately 1.41 µl of extract per 150 µl total 
volume or 0.97% concentration. 
 
 
  
For all 96 well plates each row contains one extract, from top to bottom (as displayed in 
figures and spreadsheets) they are: CBCV, CBC, THCV, CBDV, THC, CBD, CBGV and CBG. In 
the 96 well plate figures the concentration of extract decreases from left to right, from 
22.5 µl of extract per 150 µl in lane 2, to approximately 0.18 µl per 150 µl in lane 9, and in 
spreadsheet figures concentration of extracts start high on the left and decreases in every 
next right hand column. This equates to MIC results from lanes 2-9 being: 150, 75, 37.5, 
18.75, 9.38, 4.72, 2.35, 1.17 µl/ml, respectively.  
Figure 9 shows Streptococcus pneumoniae at T=0, 24 and 48 hours incubation, from top 
to bottom. Clear growth is seen in lane 9 for all extracts after incubation, however there is 
a slight decrease in cloudiness in lane 9 for rows 5 and 6 (THC and CBD) and even less 
cloudiness in the bottom most column (CBG), indicating that extract 9 was slightly more 
inhibitory at 0.18 µl per 150 µl than the other extracts.  
The top two rows, CBCV and CBC, show the least inhibitory effect as growth is observed in 
lanes 3 and 4 after 48 hours of incubation. This gives it an MIC against S. pneumonia of 
around 11 µl per 150 µl or 7.3% concentration. CBG on the other hand has an MIC of 
<0.18 µl per 150 µl or 0.12% concentration. 
Figure 8. The 96 well plate absorbencies for MRSA after 48 hours of incubation. Zoomed in 
portion shows the sudden increase of absorbencies between columns 6 and 7, indicating that 
lane 6 was the MIC for MRSA for extracts 1 and 2. 
 
 
Figure 10 shows a 96 well plate containing Enterococcus faecium after T=0, 24 and 48, 
from top to bottom. Results for THC, CBD and CBG (rows 5, 6 and 8) were well defined. 
They all showed inhibition in lane 9 to some degree, resulting in an MIC of approximately 
<0.18 µl per 150 µl or 0.12% concentration. CBC and CBCV faired the worst against E. 
faecium, with cloudiness appearing in lanes 3 and even lane 2, this resulted in an MIC of 
between 11.25 and 22.5 µl per 150 µl or 7.5 – 15% concentration. THCV resulted in an 
MIC of 1.4 µl per 150 µl or 0.93% concentration.  
 
Figure 9. 96 well plates for S. pneumoniae 
at T=0 (top), T=24 (middle) and T=48 
(bottom). 
Figure 10. 96 well plates for E. faecium 
at T=0 (top), T=24 (middle) and T=48 
(bottom). 
 
 
Table 5 shows the MICs of each whole extract for all species, with a species’ name being 
placed into the well representing the lowest concentration that produced no growth, the 
units are in µl as it represents the MIC of the whole extract, including all components and 
possible antimicrobials. Table 6 shows the actual amount of cannabinoid present in each 
extract for each lane, this has units of µg as it accounts for the percentage by mass of the 
exaggerated cannabinoid in each extract in each lane. These two must be used in 
conjunction to accurately represent the MIC of each cannabinoid.  
 
 
 
Cannabinoid 7 (CBD) produced the lowest MIC for all species, with an MIC less than 0.18 
µl per 150 µl or 0.12% by concentration, making it the most effective low concentration 
extract against the successful Gram positive organisms. Extract 9 (CBG) was the next 
lowest across all species with only B. cereus having an MIC higher than 0.12%, at 
approximately 0.24% by concentration. CBCV and CBC (extracts 1 and 2) were the extracts 
with the highest MIC for all species. They proved stronger against MRSA and S. aureus, 
with an MIC of 1.41 µl per 150 µl, but proved weakest against S. pneumoniae and E. 
faecium only achieving an MIC of 7.5% by concentration.  
CBGV and CBDV extracts (8 and 5) had strong inhibition across the spectrum of species 
tested with all MICs being above 1.41 µl per 150 µl for CBGV and all MICs being above 
0.71 µl per 150 µl for CBDV. 
THC proved a better inhibitor than its analogue THCV with extract 6 producing MICs of 
0.24% or 0.12% by concentration against all species, whereas extract 4 only had 2 species 
with an MIC of 0.24%. E. faecium proved far more resistant to THCV than THC with an MIC 
of 7.5% for THCV compared to 0.24% for THCV showing E. faecium was 31.25 times more 
susceptible to inhibition from the THC extract over its analogue’s extract. 
Figure 11 shows the 96 well plate reading for S. epidermidis after 24 hours incubation, 
emphasis has been made to show the difference in MIC between CBGV, Row G, and CBG, 
Row H. CBG has a lower MIC with lane 9 producing no detectable bacterial growth, CBGV 
however has got a much larger absorbance than the blank broth in columns 11 and 12. 
 
 
3.4 Combined extract testing 
Each extract was combined with its ‘-varin’ analogue in equal volumes. These were then 
tested out on all species that had proved successfully inhibited by cannabinoids so far and 
were included in Table 7 in triplicate alongside 1 antibiotic disk containing each of the 
individual cannabinoids separately. Figure 12 shows 2 S. aureus plates using CBG and 
CBGV on the left and THC and THCV on the right. There is a blue dot on the top right 
outer edge of each plate, this indicates the closest disc contains the lowest numbered 
individual extract. The higher numbered individual extract is the disc to the left and the 
three discs on the bottom half of the plate are the triplicate combined extract results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The 96 well plate absorbencies for S. epidermidis after at T=24. Zoomed in section 
highlights the presence of inhibition in lane 9 for extract 9 (bottom row) but not for extract 8. 
Figure 12. Comparison of S. aureus plates when tested with two different combination 
extracts. The left hand plate has extract 8 (top right), extract 9 (top left) and combination 
extracts containing both 8 & 9 (bottom three). The right plate has extract 4 (top right), extract 
6 (top left) and combination extracts of 4 & 6 (bottom three). All using 15 µl on each disc. 
 
 
 
 
 
 
 
Figure 13 shows two different combined extracts against S. pneumoniae and S. 
epidermidis, the top two plates show THC and THCV, the bottom two plates show CBGV 
and CBG. The extract combining THC and its analogue produced an average inhibition of 
14.67 mm and 17 mm against S. pneumoniae and S. epidermidis respectively, larger than 
the average value of an individual THC and THCV extract. The same applies for the CBGV 
and CBG extract combination with a mean ZOI of 19.33 mm against S. pneumoniae and 
24.67 mm average ZOI against S. epidermidis, both are closer to the stronger extract’s 
individual inhibition than the weaker individual extract. 
S. pneuoniae produced two sets of triplicate plates that had no growth at all (on the 
entire plate), extracts 1 & 2 and 5 & 7. 
 
 
 
 
 
 
Table 8 shows the triplicate ZOI values for the next series of combined extracts, which 
were chosen to combine two main type cannabinoids and two varin analogue 
cannabinoids. The chosen combinations were: CBCV and THCV, CBC and THC, CBDV and 
CBGV and finally CBD and CBG. 
Extracts 1 and 4 proves the least effective extract against all species, with only minor 
inhibition against all species except S. pyogenes which produced an average inhibition of 
15 mm. CBC and THC proved a stronger antibacterial combination than their analogue 
extracts produced when combined with a mean ZOI against E. faecium greater than 2 
times the CBCV and THCV extract achieved. Extracts 2 & 6 produced moderate inhibition 
against all species with average ZOIs in the range of 14.33 mm to 18.67 mm against E. 
faecium and S. pyogenes respectively. 
Figure 13. Comparison of S. pneumoniae (left hand plates) and S. epidermidis (right hand 
plates) using extract 4, 6 and 4 & 6 (top two plates) and extract 8, 9 and 8 & 9 (bottom two 
plates). Following the same disc layout as Figure 12. All discs contained 15 µl of extract. 
 
 
The extract combination of CBDV and CBGV was the second weakest combination tested, 
except against MRSA which it produced a mean ZOI of 18.67 mm which was slightly larger 
than the pairing of CBC and THC, but far shy of extract 7 & 9’s mean inhibition of 24.33 
mm against MRSA. CBD and CBG’s extract pairing was the strongest in this particular set 
of extracts against all species except E. faecium. The extract combination of 7 & 9 was less 
effective than the pairing of CBGV and CBG, extracts 8 and 9 from the previous test, 
against all species except for B. cereus against which it proved more effective. 
 
 
Figure 14 shows a plate of MRSA, left, and B. cereus, right, with all 4 combinations applied 
with extracts 1 & 4 being at the top, and extracts 2 & 6, 5 & 8 and 7 & 9 in anticlockwise 
order. Extract 7 & 9 produced an inhibition of 24 mm against MRSA compared with only a 
16 mm ZOI against B. cereus. 
 
 
 
 
3.5 Bacteriostatic/bactericidal testing 
Table 9 shows whether each successful extract was bacteriostatic or bactericidal, 52 out 
of 56 samples produced growth when the successful ZOIs were swabbed and streaked on 
fresh agar. Only 4 results came back bactericidal: extract 7 against B. cereus, extract 8 
against E. faecium, extract 9 against MRSA and extract 4 against S. epidermidis. 
Figure 15 shows growth of cells for all swab streaks except extract 8 which showed 
bactericidal results, however, one small colony is growing, the result is vastly different 
Figure 14. A comparison between MRSA (left plate) and B. cereus (right plate) after testing 
with combination extracts 1 & 4 (top discs), 2 & 6 (left discs), 5 & 8 (bottom discs) and 7 & 9 
(right discs). Each disc contained 15 µl of extract. 
Figure 15. The bacteriostatic/cidal results for E. faecium. The left hand plate shows swab streak 
results from the ZOIs of extract 1 (top left quadrant), extract 2 (top right), extract 4 (bottom left) 
and extract 5 (bottom right). The right hand plate contains the swab streak results for extracts 6 
(top left), extract 7 (top right), extract 8 (bottom left) and extract 9 (bottom right). 
 
 
than the clear bacteriostatic growth for other extracts, so it is classed as bactericidal. 
Slight contamination occurred in the quadrant containing extract 7’s swab results. 
Figure 16 shows the results of the test for B. cereus with the upper right hand quadrant of 
the right hand plate showing no cell regrowth from the ZOIs of extract 7. Notably the one 
of the swabs from a ZOI of extract 2 produced no cell regrowth, as did one of the streaks 
for extract 8. 
Figure 16. The bacteriostatic/cidal results for B. cereus. Following the same layout as Figure 15. 
 
  
 
 
3.6 Synthetic cannabinoid testing 
All species were tested with all 10 synthetic cannabinoid extracts. Table 10 shows the 
successful synthetic cannabinoids and their ZOIs. 5F – PB – 22 was the only synthetic 
cannabinoid that worked against more than one species, producing almost negligible ZOIs 
in some cases but enough to be detectable. It proved most successful against S. pyogenes 
and S. aureus with mean ZOIs of 10.33 mm and 9.17 mm respectively, 2 plates of which 
are found in Figure 17. The inhibition produced against B. cereus, E. faecium and S. 
pneumoniae were extremely faint, only just creating a zone of no growth, when 
compared to the natural cannabinoid extracts they fared poorly. 
 
5F – NPB – 22 and STS – 135 were effective against MRSA in the testing, but produced no 
inhibition against any other species, including its non-methicillin resistant species 
member Staphylococcus aureus. The miniscule inhibition of 5F – NPB – 22 is shown in 
Figure 17, the plate on the far right and highlighted further in Figure 18.  
 
 
 
 
Figure 17. Plates for S. pyogenes (left plate), S. aureus (middle plate) and MRSA (right plate). S. 
pyogenes and S. aureus plates have inhibition on disc 2 (from top, anticlockwise), 5F – PB – 22. 
MRSA plate shows 5F – NPB – 22 (top disc) with miniscule inhibition. Discs contained 10 µl of 
extract. 
 
 
 
3.7 MRSA genetic testing 
Due to time constraints, and personal circumstances, there was not enough time to 
complete the genetic testing to an acceptable level and so it was excluded from the study. 
It would be interesting to study this in the future, given more time. 
 
3.8 E. coli and P. aeruginosa additional extract tests 
E. coli and P. aeruginosa were both uninhibited by all extracts tested previously. A set of 
extracts with much higher concentration were made using 150 mg of Cannabis with 150 
mg of solvent. Ethanol and extracts were prepared.  
Figure 19 shows the complete lack of inhibition for all cannabinoids against both species, 
resulting in the exact same results as the normal extracts which were only 1/9th of the 
concentration. 
 
 
 
 
Figure 18. A zoomed in picture of the miniscule, yet apparent inhibition of 5F – NPB – 22 
against MRSA. Disc contained 10 µl of extract. 
 
 
 
4 Discussion 
4.1 Unsuccessful species 
E. coli, P. aeruginosa, C. albicans and C. glabrata all proved resistant to all extracts tested, 
including all solvents tested and all cannabinoid variants, including synthetic 
cannabinoids. This is in direct contrast with several studies.  
Naveed et al (2014) produced results that showed inhibition of 24.1 mm, 10.3 mm and 
22.2 mm against Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli 
using a concentration of 5 grams of Cannabis sativa leaf material and 50 ml of water or 
ethanol – a weaker concentration than used in this study, yet inhibition occurred from 
their weaker extracts. Another study by Sarmadyan et al (2013) provided results that 
Figure 19. E. coli (top plates) and P. aeruginosa (bottom plates) plates showing no inhibition 
when 10 times strength extracts were used. 
 
 
showed inhibition was produced using a disk diffusion method against E. coli but did not 
produce inhibition against P. aeruginosa. Radwan et al (2009) found that 4 isolated 
compounds from the Cannabis sativa plant had antifungal activity against Candida 
albicans, this was supported by Ali et al (2012) who found that methanol extracts of 
whole plant Cannabis sativa produced low activity against Candida albicans and high 
activity against E. coli and P. aeruginosa. Another study by Mehmedic et al (2014) showed 
that fractions of volatile oil of Cannabis sativa containing different terpenoids showed 
good and selective antifungal activity, despite containing low concentrations of 
cannabinoids. 
However, Vu et al (2016) performed a study on a wide variety of plant extracts and found 
that Cannabis sativa had no antimicrobial ability against E. coli and P. aeruginosa. 
Most referenced studies produced results with differing outcomes to the results of this 
experiment even when utilising the same extracts, sometimes at higher concentrations of 
Cannabis to solvent. In this study extracts were prepared specifically for the species 
unaffected by the regular extracts. These extracts were in a 1:1 ratio of Cannabis sativa 
material to ethanol, 10 times more concentrated than the standard extracts that proved 
so successful against Gram positive species. This was unexpected but could potentially be 
attributed to the widely varying amount of antimicrobial compounds that can be achieved 
in Cannabis sativa plants. The plants used in this study were bred to exaggerate an 
individual cannabinoid above its normal levels, in the process of doing this there may 
have been a reduction in the levels of other compounds the plants produced. It may be 
these non-cannabinoid molecules that allow the inhibition of Gram negative bacteria and 
fungi species. Alternatively, there could be slight differences between the strains of each 
species used in the different experiments, it is unlikely, but this study may have utilised a 
strain of each species that happened to be resistant to cannabinoids. Future testing could 
be done on multiple strains of each species to ensure this is not the case.  
Also, in future research, column chromatography could be used to separate and identify 
the different components of the extracts to verify if the cannabinoids are the main 
antimicrobial agent or if it is due to other compounds such as phenols that could be 
inhibiting Gram negative species and fungi species. Mahmoudi et al (2016) showed that 
methanolic leaf extracts of different varieties of Algerian fig (Ficus carica L.), containing 
many phenolic and antioxidant compounds, produced antibacterial effects against Gram 
negative bacteria, so these may be the route of inhibition in Cannabis extracts against 
 
 
Gram negative bacteria. This could also explain why studies such as Ali et al (2012) and 
Novak et al (2001) have produced inhibition against Gram negative bacteria using 
Cannabis sativa seed oils. In Novak’s study the amount of cannabinoids were assessed 
and found to be very poor, this implies the inhibition arose from other compounds. 
 
4.2 Antimicrobial activity against Gram positive species 
The results for Gram positive species were generally very successful. With all Cannabis 
extracts and solvents producing some degree of inhibition, in triplicate, against all Gram 
positive species. 
 
4.2.1 Different solvent extractions 
In the different solvent testing against MRSA using CBG, the methylated spirit extract 
proved to be the strongest inhibitor when compared with ethanol extracts and the two 
water extracts incubated at 37 °C for 24 hours or 70 °C for 2 hours and then 22 hours at 
37 °C. 
The methylated spirit and ethanol extracts had very similar ZOIs for all volumes, with only 
a 3 mm and 2 mm average ZOI difference between 15 and 60 µl and for methylated spirit 
and ethanol respectively. This could be due to CBG being a powerful antibacterial, 
displaying an MIC of 0.13 µg/ml or 1.17 µl/ml of extract, and being close to the limit of its 
diffusion area which is limiting its ZOI sizes as no zones in the whole study produced more 
than a 30 mm ZOI. The water extracts proved to be less effective, inhibition zones in all 
cases were smaller than those for ethanol or methylated spirit. The water that was 
incubated for 2 hours at 70 °C proved less effective than the water extract incubated 
solely at 37 °C for volumes of 15, 30 and 60 µl. But for volume 45 µl it proved to be very 
slightly more effective. A T-test performed for the 45 µl produced a p-value of 0.78, larger 
than the threshold p-value of 0.05, determining the results are not statistically different. 
T-tests performed between methylated spirit and ethanol extracts at 15, 30 and 45 µl 
showed p-values of: 1, 0.23 and 0.23, respectively, showing no statistical differences 
between the values. 
Wasim et al (1995) produced results using a well diffusion method showing that ethanolic 
and petroleum ether extracts inhibited growth of Gram positive and Gram negative 
bacteria and against the fungi tested. Their water extracts did not produce any 
 
 
antimicrobial activity at all. This is in contrast to this experiment as the results from this 
test showed that water extracts both produced inhibition against all Gram positive 
species tested. However, the results for Candida albicans were the same in both studies 
for aqueous extracts. No inhibition produced. The studies differed in most of the species 
studied, with only S. aureus and C. albicans being used in both studies. 
 
4.2.2 Ethanol extracts at 15 µl and MICs 
The cannabichromene type Cannabis extracts were continuously the smallest zone-
producing extracts, this contrasts with some studies. A study published by Turner and 
Elsohly (1981) produced results showing antibacterial activity was strong against Gram 
negative and positive species, Appendino et al (2008) also found that CBC was a strong 
inhibitor. This appears contradictory to results obtained in this study for ZOIs, as 
consistently the CBC and CBCV extracts produced weak inhibition, with a ZOI range 
against all species of 6 – 10.67 mm for CBCV and 6 – 11.67 for CBC. Appendino et al 
reported MIC values of 2 µg/ml of CBC against S. aureus and MRSA, which appears more 
effective than the extract tested in this study with an MIC of 9.4 µg/ml. However, 
Appendino et al’s study used pure (>98%) cannabinoids from Cannabis sativa and so their 
extracts contained far more cannabinoids than the CBC chemotype Cannabis used in this 
study which had cannabinoid percentages by weight of 1.8 and 2, for CBCV and CBC.  
This means the extract tested contained at most 1.8-2% CBCV and CBC which equates to 
an MIC of 0.17-0.19 µg of CBC/ml, as shown in Table 6 which shows the MIC in µg/ml for 
each extract’s actual cannabinoid concentration in each lane. This study found CBC was at 
a concentration of 0.19 µg/ml when it produced inhibition, a considerably lower MIC than 
Appendino’s study, however this experiment could not discern which compounds within 
the extract were responsible for any inhibition, only whether inhibition occurred or not. 
98% of the botanical raw material used in extract 2 was not cannabidiol, so it was a very 
real chance that other compounds were contributing to the inhibition, this should be 
studied further. Ali et al’s study (2012) produced an MIC result of 50 µg/ml against S. 
aureus using a methanol whole plant extract, significantly higher than even the highest 
MIC produced in this experiment where CBCV and CBC both had an MIC of 9.3 µl/ml, 
Strangely, the study performed by Ali showed that the same whole plant extract had a 
MIC against E. coli and P. aeruginosa of 25 µg/ml and 12.5 µg/ml, whereas this study 
produced no inhibition for any species. 
 
 
It is important to take into account the concentration of each cannabinoid in the extracts 
as the Cannabis sativa material received from G. W. Pharmaceuticals has a range of 1.8% 
cannabinoid by weight (for CBCV, extract 1) and 15.8% cannabinoid by weight (for THC, 
extract 6). Unfortunately, some studies relating to the antimicrobial ability of Cannabis 
sativa do not contain information on the exact amounts of cannabinoids in the extracts, 
only that they are present. 
The THC type extracts produced generally moderate to strong inhibition against most 
Gram positive species. This has been known for several decades, with Van Klingeren and 
Ten Ham (1976) producing results showing THC and CBD had an MIC against 
Staphylococci and Streptococci of 1-5 mug/ml, this is much higher than the MICs of the 
THC extract tested in this experiment which had <0.52 µg/ml for the Staphylococcus and 
Streptococcus species. This could easily be explained by the large increases in THC yields 
that are now achievable in comparison to 4 decades ago. Their study also provided results 
showing that Gram negative bacteria were resistant to THC and CBD, which aligns with 
the results of this study. THCV has, as far as could be found, no published research 
specifically stating its efficacy as an antimicrobial, this is unusual as the cannabinoid was 
isolated and identified at the beginning of the 1970s (Gill et al, 1970).  
Appendino et al (2008) produced results showing MIC ranges of 0.5 to 2 µg/ml against 
multi-drug resistant S. aureus and the major methicillin-resistant S. aureus strains, these 
were occurring in hospitals in the UK at the time (Richardson and Reith, 1993). In this 
experiment, the THC extract produced an MIC of 4.72 µl/ml against MRSA, equating to an 
MIC 0.26 µg/ml of pure THC, compared to the MIC of 0.5 µg/ml achieved against one 
strain of MRSA used in Appendino’s study. A similar MIC for the THC extract was achieved 
in Appendino’s study as in this one, both having an MIC of 2 µg/ml. 
CBD type Cannabis has been known to be antibacterial since at least 1976 when Van 
Klingeren and Ten Ham showed it produced inhibition against Staphylococci and 
Streptococci species, it has been understood to exist since the 1940s and had its structure 
discovered in 1963 (Burstein, 2015). Yet there is still a lack of research on isolated 
cannabinoids (or at least Cannabis bred to have exaggerated chemotypes as in this study). 
Appendino et al (2008) provided one of the only published research papers studying 
isolated cannabinoids and not just whole plant materials. Their study provided an MIC for 
cannabidiol of 1 µg/ml which is slightly lower than the value for the CBD extract in this 
experiment (1.17 µg/ml). 
 
 
The CBG extracts proved to have generally strong inhibition against the Gram positive 
species with inhibition size data ranging from 17 to 28 mm. CBGV was a worse inhibitor 
than its non-varin analogue for all Gram positive organisms but it must be taken into 
account that the CBG type Cannabis used in this experiment had a CBG concentration of 
11.1% by weight of raw material, CBGV on the other hand had a CBGV concentration of 
3.6% by weight. This means when comparing the MICs of the two extracts it is important 
to reference Table 5 and Table 6 which show each species’ MIC for the amount of extract 
per 150 µl well and the amount of cannabinoid present in 1 ml, respectively. In the 96 
well plates the CBG extract had lower MICs for all species than those of the CBGV 
extracts. However, when comparing the actual amount of cannabinoid present in each of 
the wells for inhibition to take place, CBGV had a lower MIC than CBG against B. cereus, 
with 0.16 µg/ml and 0.26 µg/ml respectively, and also against S. aureus and S. epidermidis 
where CBGV had an MIC of 0.08 µg/ml and CBG had an MIC of 0.13 µg/ml. These results 
were stronger than penicillin against S. aureus, where Rubin et al (2011) showed an MIC 
for penicillin was 1 µg/ml. This indicates CBGV is potentially 12.5 times stronger than 
penicillin for this species. The MIC obtained for CBG was smaller than in Appendino et al’s 
2008 study. They recorded an MIC of 1 µg/ml for 5 of their 6 strains, with one MRSA 
strain having an MIC of 2 µg/ml, whereas this experiment showed MICs for CBG of 0.13 
µg/ml. A study by Borchardt et al (2008) showed that a Cannabis sativa ethanol extract 
produced inhibition of 25 mm against S. aureus and found no inhibition against Gram 
negative species they used in the study. The closest result from this experiment was the 
CBG extract, which produced a mean inhibition of 23 mm, however only 15 µl of extract 
was tested in this study while Borchardt et al used 50 µl.  
The results from the ethanol compounds against Gram positive organisms produced 
contradictory results to many studies, particularly focussing on the different results for 
Gram negative. Eisohly et al (1982) found that CBC was a superior antibiotic to THC and 
CBD, which is the opposite according to the results obtained in this study. CBC was shown 
to have an MIC against MRSA of 0.19 µg/ml, whereas THC and CBD had MICs against 
MRSA of 0.18 and 0.15 µg/ml, respectively, showing that CBC was a slightly less effective 
antibacterial than THC and CBD. 
The results obtained in this study showed that there was a noticeable difference between 
the chemical phenotypes of cannabis that were used to prepare each extract. CBC, and its 
varin analogue, consistently performed poorly against most species when compared with 
 
 
the other chemical phenotype extracts, which all proved far more successful. It is not 
possible from this experiment to deduce whether these differences are specifically due to 
the different cannabinoids that are exaggerated in each extract, or whether there are 
other antimicrobials present in varying levels throughout the different plants which could 
also be responsible. However, there was a noticeable pattern that the main type 
cannabinoid extracts (CBC, CBD, CBG and THC) all proved more successful inhibitors than 
their varin analogue extracts did, this adds weight to the argument that the cannabinoids 
are a reason for their antimicrobial activity. The lower inhibitory ability of the varin 
analogues may indicate that a propyl side chain attached to the aromatic ring (instead of 
a pentyl side chain found in the main type cannabinoids) has a detrimental affect on the 
molecules antibacterial activity. 
 
4.2.3 Combined Extracts 
Combined ethanol extract testing produced results that showed slightly unexpected 
values, at face value. Extracts 8 and 9 (CBGV and CBG) produced inhibition zones of 
around 10 mm and 20 mm against E. faecium and inhibition zones of approximately 19 
mm and 27 mm against S. aureus when tested individually. But when compared to the 
combined extract results for 8 and 9, both species had a shift toward the stronger CBG 
zone sizes than they did to the average of the two individual extracts. This could 
potentially be explained due to the differing concentration of each exaggerated 
cannabinoid in the different extracts. When mixed together in equal volumes and 
pipetted (15 µl) onto a blank antibiotic disc, there was a marked difference in cannabinoid 
amount between the two, with CBGV being present in a mass of approximately 0.27 µg 
and CBG being present in 3 times that amount, approximately 0.83 µg. This can be the 
explanation behind the perceived synergistic antibacterial effect they share as CBG is 3 
times more prevalent in the extract. T-tests performed between extracts 8 and 9 showed 
a p-value of 0.0006, below the threshold of 0.05, meaning the data was significantly 
different. Between extract 8 and the combination extract, containing 8 & 9, a p-value of 
0.0001 was produced, also showing a statistical difference between the extract’s ZOIs. 
Extract 9 produced a p-value of 1 when compared with the combined extract, implying 
there was no significant difference between the two extract’s resulting inhibition sizes 
and thus helps confirm that any synergistic antibacterial effect that appeared in the test is 
 
 
highly likely to be a result of CBG in the extract, and not a combination effect of the CBG 
and its varin analogue CBGV. 
Likewise, average ZOI sizes for the combination extract containing extracts 4 & 6 were far 
closer to the individual extract containing THC (4) than it was to the individual THCV 
extract. On first inspection this would imply a synergistic antibacterial effect between the 
two extracts. However, extract 4 had 5% THCV by weight while extract 6 had 15.8% THC. 
The 3 times more concentrated cannabinoid could easily explain the difference in 
antibacterial activity between the two, instead of implying that THCV has a less active 
structure. This could be studied further with equal concentrations of cannabinoids. 
T-tests performed showed p-values of 0.0002 and 0.0009 between extracts 4 and 6, and 
extract 4 against the combined extract, respectively. Showing statistically significant 
differences in the results. The p-value obtained for extract 9 and the combination extract 
was 0.057, above the 0.05 threshold, and so is not significantly different. 
An interesting set of results for extract combination 7 & 9 were produced. Both 
cannabinoids are expressed in large quantities compared to most samples, with 13% and 
11.1%, a much smaller difference than the other two combined extracts discussed above. 
The results for some species do not fall near to the average as would be expected. Against 
S. pneumoniae extract 7 produced 14.67 mm average ZOI, while extract 9 produced 20 
mm on average. When combined, the results gave an average ZOI of 19 mm. Comparing 
this with the results against B. cereus; extract 7 produced 23.33 mm average ZOI, while 
extract 9 produced 16 mm on average. When combined, the results gave an average ZOI 
of 17.67 mm. Despite the CBG extract (9) being a stronger inhibitor of growth in S. 
pnuemoniae and weaker in B. cereus than the CBD extract (7), the average ZOI for the 
combined extract was much closer to extract 9’s inhibition size than extract 7’s. Even in 
the case where the CBD-type individually produced a 7 mm larger diameter of inhibition 
than extract 9 did individually, the combined extract was 5.66 mm smaller than extract 
7’s. Potentially this could mean that the CBG type inhibited the CBD cannabinoid from 
being effective, or it could mean that there was not enough CBD present on the disc to 
diffuse far enough, or cause enough inhibition. 
For some reason extracts 1 & 2 and 5 & 7 against S. pneumoniae produced no growth at 
all on their plates and so no results could be obtained. No reason was found for the 
complete lack of growth for these 2 triplicates.  
 
 
Unfortunately, there is no discernible research relating to combining particular 
cannabinoids to try and enhance or decrease antimicrobial activity. Studies that have 
been used for comparison throughout this study either use whole type Cannabis with a 
natural spectrum of cannabinoids (meaning they contained fewer of the rarer 
cannabinoids, such as CBG and the varin analogues, than the Cannabis samples received 
from E. De Meijer (G. W. Pharmacetuicals) for this study. CBG was found to be less than 
10% cannabinoid fraction and never more than total THC or CBD concentrations in 66 
Cannabis sativa plants (Welling et al, 2016)) or they used isolated or fractions of Cannabis 
extracts. 
 
 
4.2.4 Bacteriostatic/bactericidal results 
Research pertaining to the bactericidal or bacteriostatic properties of cannabinoids has 
not been performed. Very few studies used isolated, or high concentrations of, 
cannabinoids. Appendino et al’s (2008) study was the most in-depth to date, using purer 
forms of cannabinoids and producing results against a variety of species, but even this has 
no mention of bactericidal or bacteriostatic properties of Cannabis sativa. More research 
must be done on cannabinoids antimicrobial activity and methods of inhibition. 
The results from this study, regarding its bactericidal or bacteriostatic, were unreliable. 
Contamination occurred in many plates and, when repeated, results proved fairly 
inconsistent, with only 4 swabs producing bactericidal results in triplicate. 
Some results, such as in Figure 16, show that there was a lack of consistency in the results 
for several species. Extract 8 only produced 2 streaks of growth against B. cereus in that 
plate, yet the swabbing and transferring technique were the same for all the 3 swabs. 
 
4.2.5 Result viability 
Some of the inhibition zones produced in these experiments against several species were 
extremely obvious. S. pneumoniae, B. cereus, S. aureus and MRSA all produced very 
clearly defined ZOIs in almost all cases, S. epidermidis also consistently produced quite 
well defined ZOI edges. S. pyogenes and E. faecium both produced poorly defined 
inhibition zones in almost all plates. It could be due to the heterogeneity of the strains 
with varying levels of susceptibility to the cannabinoids. This made measuring such result 
 
 
harder, and more prone to personal opinion, than the clearly defined measurements 
taken for the other species. This means that ZOI sizes for S. pyogenes and E. faecium 
should be taken cautiously, instead attention should be paid to the MIC values obtained 
as these are more accurate considering the lawns of both bacteria seemed resistant to 
growing on solid agar.  
All MIC values should be accurate, occasionally a plate would contain contamination and 
be removed from the measurements leaving duplicate values to compare and deduce an 
average. But MIC results were consistent in successful plates, so the data appeared 
consistent when uncontaminated. 
Bactericidal and bacteriostatic testing produced a significant number of bacteriostatic 
results. This is believed to be erroneous and due to the method used, as a small slip could 
cause the swab or toothpick to touch the un-inhibited lawn of bacteria and become 
inoculated with live cells which would then provide a false bacteriostatic result. 
 
4.3 Synthetic cannabinoids 
As the synthetic cannabinoids tested in this study were not isomers of the natural 
compounds being tested from the Cannabis sativa plant, and only acted upon the same 
CB1 and CB2 receptors in animals, positive results were not expected. It was surprising 
then to see any inhibition at all. 
Synthetic cannabinoid 5F – PB – 22 produced very minor, almost negligible, inhibition 
against B. cereus and E. faecium, and very slightly larger inhibitions against S. aureus, S. 
epidermidis, S. pnuemoniae and S. pyogenes. T-tests performed for results of B. cereus 
and E. faecium against the DMSO blank disc produced p-values of 0.116 and 0.007, 
respectively. Showing a significant difference between the results of 5F – PB – 22 and 
DMSO with no cannabinoid for E. faecium, but not significantly different against B. cereus. 
5F – PB – 22 had no inhibition against MRSA. Whereas 5F – NPB – 22, an indazole 
derivative of 5F – PB -22 (Kohyama et al, 2017), showed slight inhibition against MRSA. The 
only difference between the compounds is a nitrogen atom replacing a carbon atom in a 
pentyl ring. 
STS – 135 was the only other synthetic cannabinoid that produced any antibiotic activity, 
only against MRSA. It produced a slightly smaller ZOI than 5F – NPB – 22 did. A T-test 
 
 
performed for the two sets of data produced a p-value of 0.23, above the 0.05 threshold, 
and so are not significantly different. 
As the structures of the synthetic cannabinoids tested in this experiment were not closely 
related to the natural cannabinoids being tested, it does not help determine whether the 
antimicrobial properties of the 8 extracts tested were due to the presence of 
cannabinoids. It would be interesting in future research to try comparing synthetic 
cannabinoids that contain very similar structures to natural cannabinoids. Figure 20, 
derived from Castaneto et al (2014), shows the similarities in structure between THC, the 
main cannabinoid in extract 6 of this study, and HU – 210, a synthetic cannabinoid. In this 
hypothetical study both compounds could be tested, the Cannabis sativa THC chemotype 
extract against the pure HU – 210 synthetic cannabinoid. Any large differences could 
imply that there are other antimicrobial compounds working in the whole plant extract 
than just the main cannabinoid that it has been bred to exaggerate. 
There is currently no research available on the applications of synthetic cannabinoids as 
antimicrobial agents. The efficacy shown in this experiment is low. The concentration of 
the synthetic cannabinoid extracts were 10mg/ml, much higher than the concentration of 
the natural cannabinoids in the extracts used in this study, and yet they produced either 
none, or very little inhibition. This indicates synthetic cannabinoids, or at least the 10 
tested in this study, are ineffective antimicrobials. 
 
5 Limitations of the study and future improvements 
There were several aspects of the study that could have yielded more meaningful results. 
Firstly, the selection, and subsequent availability, of only 11 species, 7 of which were 
Gram positive, allowed for only a small sample size for Gram negative and fungal species. 
In future studies, purchasing of a wider variety of microorganisms would be a more 
Figure 20. The molecular structure of Delta-9-THC (THC) and HU – 210, a synthetic cannabinoid. 
 
 
meaningful approach over solely using the organisms held by the university technicians. 
More Gram negative and fungi species were needed in this experiment. The sample size 
of 2 is considered too low to be able to draw a general conclusion for the extract’s 
efficacy against Gram negative bacteria and fungi. Potentially more than one strain could 
have been used for each species as this could have identified if there was a difference in 
antimicrobial ability between strains of the same species and could potentially explain 
why some Cannabis sativa apparently works against Gram negatives and some do not. 
Secondly, a few varieties of wild Cannabis sativa grown without human intervention to 
manipulate cannabinoid levels, would have been interesting to incorporate into the 
study. It could provide a more balanced cannabinoid profile and could help to decipher 
where the antimicrobial properties of Cannabis come from. This could further be 
supplemented using pure isolates of each of the major cannabinoids, buying them where 
available, and using column chromatography to isolate any cannabinoids that are too 
expensive or are not sold. Alternatively, it would be useful if Cannabis sativa variants 
could be found that exaggerated individual cannabinoids, like the Cannabis used in this 
study, but at the same levels. If all Cannabis samples contained, for example, 10% of the 
chosen cannabinoid then it could allow for much more meaningful comparisons between 
the cannabinoids. 
The extracts themselves did not actually prove that the cannabinoids, that were 
exaggerated differently in each individual plant, were responsible for any antimicrobial 
inhibition they may have caused. Given more time, it would be interesting to use column 
chromatography in the future to prepare fractions of each plant chemotype and testing 
each one’s antimicrobial ability. This would allow for genuine deduction of where the 
inhibitory effects of Cannabis sativa come from and whether it is due to a handful of 
compounds or a large collection of compounds that work better when combined.  
The volumes of extracts in the main ethanolic test of this experiment were only 15 µl per 
disc. In future it would be more useful to use a variety of volumes, at least 3.75, 7.5, 30, 
and 60 µl, this could allow for weaker extracts to potentially show their inhibition better 
and stronger extracts to more accurately demonstrate their antimicrobial properties. This 
could be used to create graphs to help determine MICs. 
The synthetic compounds used in this study provided little positive data. In future it 
would be interesting to test synthetic analogues that are more closely related to the 
natural cannabinoids as this would help to figure out whether the cannabinoids are the 
 
 
source of Cannabis sativa’s antimicrobial ability, and if so which arrangements are most 
effective. This could have ramifications for antibiotic synthesis in the future. 
In future experiments, bactericidal and bacteriostatic testing should be performed 
differently than in this study. The method used for this experiment was too easily prone 
to false negative results for bactericidal results, as the ZOI of some species were small, 
any swab or toothpick used could accidentally be contaminated by the lawn of surviving 
microorganism, which could explain why there are so many bacteriostatic results in this 
experiment. Using a similar technique to the MIC 96 well plates used in this experiment, 
dilutions of each extract could be used against broth with the same concentration of 
colonies. The weakest extract that works could then be transplanted to an agar plate and 
incubated to see if the species regrows, less chance of contamination would mean more 
meaningful results. 
Given the time, it would have been interesting to try many combinations of extracts for 
the combination testing including in combinations of 3 or more and in higher 
concentrations. This could produce results proving if a wide variety of cannabinoids is 
more powerful, or in some cases successful at all, against certain species. There are not a 
lot of studies that have been performed that combine several cannabinoids, they usually 
contain either purer isolates or whole Cannabis sativa extracts that do not contain minor 
cannabinoids in relevant concentrations. 
Finally, the literature on Cannabis sativa and its use as an antimicrobial is sparse. Some of 
the cannabinoids tested in this study have essentially no studies regarding their ability as 
antimicrobials, mainly the varin analogues; CBCV, CBDV, CBGV and THCV. In the future it 
would be ideal for more research to be done in the field, focusing on rarer cannabinoids 
as well as the major 4 types (CBC, CBD, CBG and THC), this could be used for much 
stronger comparison and debate. 
 
Conclusion 
The results from this study showed that Cannabis sativa extracts were effective 
antimicrobials, in vitro, against all species of Gram positive organisms tested and that 
varying degrees of inhibition were achieved by the different chemical phenotypes of the 
plant. Gram negative bacterial and fungal species that were tested all proved to be 
resistant, even to specifically made extracts 10 times the concentration of the successful 
 
 
Gram positive extracts. The negative results are contrasted by studies that have shown 
that Cannabis and its isolated compounds are antimicrobial against these 
microorganisms, but the results are corroborated by studies which have also concluded 
that Cannabis extracts do not work against Gram negative species and fungi tested. What 
makes this more interesting is that the Cannabis sativa varieties used in this study 
contained high levels of the desired cannabinoid. So, when compared with isolated 
cannabinoids like Appendino et al (2008) used in their study, the results would have been 
expected to have a close relationship. But this was not the case for some species and 
cannabinoids and so, if the cannabinoids were the source of antimicrobial activity, why 
did these extracts show no inhibition against Gram negative species when studies like 
Naveed et al (2014) and Ali et al (2012) showed whole plant cannabis resulted in inhibition 
against Gram negative species? The cannabinoids present in the Cannabis sativa used 
here were bred to be exaggerated and so undoubtable in higher levels than the studies 
that produced inhibition against Gram negative species, yet the results were opposite. 
This study provided results that proved different and distinct chemical phenotypes of 
Cannabis sativa produce different antibacterial activity. They showed that extracts 
containing Cannabis bred to exaggerate cannabichromene (CBC) and cannabichromavarin 
(CBCV) were the least effective against all species on average for ZOIs and MICs. 
Cannabigerol (CBG) was the Cannabis extract that proved the strongest, in most cases, for 
ZOIs and MICs. Its analogue, CBGV, had equally low MICs but due to it containing only 
around 1/3 of the desired cannabinoid than the CBG type cannabis, it did not produce 
equal results regarding ZOIs. Cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) 
both proved to be strong antimicrobials for ZOIs and MICs with their analogues being 
slightly worse. The results imply that the different cannabinoid emphasised in each 
extract is responsible for the differing ZOIs and MICs but this cannot be proven as there 
are too many potentially antimicrobial agents within the plant that may be responsible. 
There is a lack of comparable evidence in the field of Cannabis antimicrobials, especially 
regarding varin analogues, the amount of studies is currently small, and the results 
obtained in said studies are constantly contradictory. This emphasises that the Cannabis 
sativa plant could have an abundance of antimicrobial compounds in its arsenal, not just 
the popular cannabinoids. These compounds may be dependent on the genetics of each 
plant, and therefore are widely variable, and thus could be responsible for the 
contradictory results that have been found. More research needs to be done in this area 
 
 
to understand the mechanisms and sources of the Cannabis sativa’s antimicrobial activity, 
and also whether any of these effects are retained in vivo, as nearly all research to date 
has focused on inhibiting microorganisms in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
Ali, E. M. M., Almagboul, A. Z. I., Khogali, S. M. E. & Gergeir, U. M. A. (2012) ‘Antimicrobial 
Activity of Cannabis sativa L.’ Chinese Medicine, 3 pp. 61-64. 
 
Aldrich M. (1997) History of therapeutic cannabis. Jefferson, N.C. : McFarland & Co 
Andre, C., Hausman, J. and Guerriero, G. (2016) ‘Cannabis sativa: The Plant of the 
Thousand and One Molecules.’ Frontiers in Plant Science, 7(19). 
 
Andre, C., Larondelle, Y. and Evers, D. (2010) ‘Dietary Antioxidants and Oxidative Stress 
from a Human and Plant Perspective: A Review.’ Current Nutrition & Food Science, 6(1) 
pp. 2-12. 
 
Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., Smith, E. & 
Rahman, M. (2008) ‘Antibacterial cannabinoids from Cannabis sativa: a structure-activity 
study.’ Journal of Natural Products, 71(8) pp. 1427-1430 
 
Bodake, H. B., Panicker, K N., Kailaje, V. V. and Rao, K. V. (2002) ‘Chemopreventive effect 
of orange oil on the development of hepatic preneoplastic lesions induced by N-
nitrosodiethylamine in rats: an ultrastructural study.’ Indian Journal of Experimental 
Biology, 40(3) pp. 245-251. 
 
Borchardt, J. R., Wyse, D. L., Sheaffer, C. C., Kauppi, K. L., Fulcher, G., Ehike, N. J., 
Blesboer, D. D. and Bey, R. F. (2008) ‘Antimicrobial activity of native and naturalised 
plants of Minnesota and Wisconsin.’ Journal of Medicinal Plants and Research, 2(5) pp. 
098-110. 
 
Bradley, S. G., Munson, A. E., Dewey, W. L. and Harris, L. S. (1977) ‘Enhanced susceptibility 
of mice to combinations of delta 9-tetrahydrocannabinol and live or killed gram-negative 
bacteria.’ Infection and Immunity, 17 pp. 325-329. 
 
Burstein, S. (2015) ‘Cannabidiol (CBD) and its analogs: a review of their effects on 
inflammation.’ Bioorganic & Medicinal Chemistry, 23(7) pp. 1377-1385. 
 
Carvalho, A., Hansen, E. K., Kayser, O., Carlsen, S. and Stehle, F. (2017) ‘Designing 
microorganisms for heterologous biosynthesis of cannabinoids.’ FEMS Yeast Research, 
17(4). 
 
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S. and Huestis, 
M. A. (2014) ‘Synthetic cannabinoids: Epidemiology, pharmacodynamics and clinical 
implications.’ Drug and Alcohol Dependencei, 144 pp. 12-41. 
 
 
 
Chen, J. W., Borgelt, L. M. and Blackmer, A. B (2019) ‘Epidolex (Cannabidiol): A New Hope 
for Patients With Dravet or Lennox-Gastaut Syndromes.’ Annals of Pharmacotherapy.  
 
Chong, M. S., Wolff, K., Tanton, C., Winstock, A. and Silber, E. (2006) ‘Cannabis use in 
patients with multiple sclerosis.’ Multiple Sclerosis Journal, 12(5) pp. 646-651. 
 
Colorado Department of Revenue. (2019) Marijuana Tax Data. [Online] [Accessed on 18th 
February 2019] https://www.colorado.gov/pacific/revenue/colorado-marijuana-tax-data 
 
Cueva, C., Moreno-Arribas, M., Martín-Álvarez, P., Bills, G., Vicente, M., Basilio, A., Rivas, 
C., Requena, T., Rodríguez, J. and Bartolomé, B. (2010) ‘Antimicrobial activity of phenolic 
acids against commensal, probiotic and pathogenic bacteria.’ Research in Microbiology, 
161(5) pp. 372-382. 
 
D’Alessio, P. A., Bisson, J. F. and Bene, M. C. (2014) ‘Anti-stress effects of d-limonene and 
its metabolite perillyl alcohol.’ Rejuvenation Research, 17(2) pp. 145-149. 
 
Davis, W. M. & Hatoum, N. S. (1983) ‘Neurobehavioral actions of cannabichromene and 
interactions with delta9-tetrahydrocannabinol.’ General Pharmacology: The Vascular 
System, 14(2) pp. 247–252. 
 
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allara, M., Bisogno, T., Petrosino, S., Stott, C. 
G. & Di Marzo, V. (2011) ‘Effects of cannabinoids and cannabinoid-enriched Cannabis 
extracts on TRP channels and endocannabinoid metabolic enzymes.’ British Journal of 
Pharmacology, 163(7) pp. 1479-1494. 
 
Do Vale, T. G., Furtado, E. C., Santos Jr, J. G. and Viana, G. S. (2002) ‘Central effects of 
citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba 
(mill.) n. e. Brown’ Phytomedicine 9(8) pp. 709-714. 
 
Eisohly, H. N., Turner, C. E., Clark, A. M. & ElSohly, M.A. (1982) ‘Synthesis and 
antimicrobial activities of certain cannabichromene and cannabigerol related 
compounds.’ Journal of Pharmaceutical Sciences 71(12) pp. 1319-1323. 
 
Elsohly, M. A. (2007) ‘Marijuana and the Cannabinoids.’ Forensic Science and Medicine, 
pp. 268. 
 
ElSohly, M. A. & Slade, D. (2005) ‘Chemical constituents of marijuana: The complex 
mixture of natural cannabinoids.’ Life Sciences, 78(5) pp. 539-548. 
 
Fellermeier, M. and Zenk, M. H. (1998) ‘Prenylation of olivetolate by a hemp transferase 
yields cannabigerolic acid, the precursor of tetrahydrocannabinol.’ FEBS Letters, 427(2) 
pp. 283-285. 
 
 
 
Fernandez, M. A., Garcia, M. D. & Saenz, M. T. (1996) ‘Antibacterial activity of the 
phenolic acids fractions of Scrophularia frutescens and Scrophularia sambucifolia.’ Journal 
of Ethnopharmacology, 53(1) pp. 11-14. 
Filbey, F. and Yezhuvath, U. (2013) ‘Functional connectivity in inhibitory control networks 
and severity of cannabis use disorder.’ The American Journal of Drug and Alcohol Abuse, 
39(6) pp. 382-391. 
 
Gagne, S. J., Stout, J. M., Liu, E., Boubakir, Z., Clark, S. M. and Page, J. E. (2012) 
‘Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic 
route to plant polyketides.’ Proceedings of the National Academy of Sciences of the 
United States of America, 109(31) pp. 12811-12816. 
 
Gaoni, Y. and Mechoulam, R. (1964) ‘Isolation, structure and partial synthesis of an active 
constituent of hashish.’ Journal of American Chemical Society, 86 pp. 1646-1647. 
 
Gill, E. W., Paton, W. D. M. and Pertwee, R. G. (1970) ‘Preliminary Experiments on the 
Chemistry and Pharmacology of Cannabis.’ Nature, 228(5267) pp. 134-136. 
 
Gomes, F., Issy, A., Ferreira, F., Viveros, M., Del Bel, E. and Guimarães, F. (2015) 
‘Cannabidiol Attenuates Sensorimotor Gating Disruption and Molecular Changes Induced 
by Chronic Antagonism of NMDA receptors in Mice.’ International Journal of 
Neuropsychopharmacology, 18(5). 
 
Gowers, W. R. (1888) ‘A Manual of Diseases of the Nervous System.’ Philadelphia, PA: P. 
Blakiston Son & Co 
 
Hammond, C. T. & Mahlberg, P. G. (1977) ‘Morphogenesis of capitate glandular hairs of 
Cannabis sativa (Cannabaceae)’. American Journal of Botany, 64 pp. 1023–1031. 
 
Hill, A. J., Williams, C. M., Whalley, B. J. & Stephens, G. J. (2012) ‘Phytocannabinoids as 
novel therapeutic agents in {CNS} disorders.’ Pharmacology and Therapeutics, 133(1) pp. 
79–97. 
 
Jiang, H., Wang, L., Merlin, M., Clarke, R., Pan, Y., Zhang, Y., Xiao, G. and Ding, X. (2016) 
‘Ancient Cannabis Burial Shroud in a Central Eurasian Cemetery.’ Economic Botany, 70(3) 
pp. 213-221. 
 
Jenkins, R., Burton, N. and Cooper, R. (2014) ‘Proteomic and genomic analysis of 
methicillin-resistant Staphylococcus aureus (MRSA) exposed to manuka honey in vitro 
demonstrated down-regulation of virulence markers.’ Journal of antimicrobial 
chemotherapy, 69 pp. 603-615.  
 
 
 
Jett, J., Stone, E., Warren, G. and Cummings, K. M. (2018) ‘Cannabis use, lung cancer and 
related issues.’ Journal of Thoracic Oncology, 13(4) pp. 480-487. 
 
Joy, J. E., Watson, S. J. and Benson, J. A. (1999) ‘Marijuana and medicine: assessing the 
science base.’ Choice Reviews Online, 37(4). 
 
Kohyama, E., Chikumoto, T., Tada, H., Kitaichi, K. and Ito, T. (2017) ‘Analytical 
differentiation of quinolinyl- and isoquinolinyl-substituted 1-(5-fluoropentyl)-1H-indole-3-
carboxylates: 5F-PB-22 and its ten isomers.’ Forensic Toxicology, 35(1) pp. 56-65. 
 
Kurekci, C., Padmanabha, J., Bishop-Hurley, S., Hassan, E., Al Jassim, R. and McSweeney, 
C. (2013) ‘Antimicrobial activity of essential oils and five terpenoid compounds against 
Campylobacter jejuni in pure and mixed culture experiments.’ International Journal of 
Food Microbiology, 166(3) pp. 450-457. 
 
Leanza, L., Managò, A., Zoratti, M., Gulbins, E. and Szabo, I. (2016) ‘Pharmacological 
targeting of ion channels for cancer therapy: In vivo evidences.’ Biochimica et Biophysica 
Acta (BBA) - Molecular Cell Research, 1863(6), pp. 1385-1397. 
 
Long, T., Wagner, M., Demske, D., Leipe, C. and Tarasov, P. (2016) ‘Cannabis in Eurasia: 
origin of human use and Bronze Age trans-continental connections.’ Vegetation History 
and Archaeobotany, 26(2) pp. 245-258. 
 
Lotan, I., Treves, T. A., Roditi, Y., and Djaldetti, R. (2014). ‘Cannabis (medical marijuana) 
treatment for motor and non-motor symptoms of Parkinson disease: an open-label 
observational study.’ Clinical Neuropharmacoly, 37(2) pp. 41–44. 
 
Luo, X., Reiter, M. A., d’Espaux, L., Wong, J., Denby, C. M., Lecher, A., Zhang, Y., 
Grzbowski, A. T., Harth, S., Lin, W., Lee, H., Yu, C., Shin, J., Deng, K., Benites, V. T., Wang, 
G., Baidoo, E. E. K., Chen, Y., Dev, I., Petzold, C. J. and Keasling, J. D. (2019) ‘Complete 
biosynthesis of cannabinoids and their innatural analogues in yeast.’ Nature. 
 
Lutge, E., Gray, A. and Siegfried, N. (2013) ‘The medical use of Cannabis for reducing 
morbidity and mortality in patients with HIV/AIDS.’ Cochrane Database of Systematic 
Reviews. 
 
Machado Rocha, F. C., Stefano, S. C., De Cassia Haiek, R., Rosa Oliviera, L. M. Q. and Da 
Silveira, D. X. (2008) ‘Therapeutic use of Cannabis sativa on chemotherapy-induced 
nausea and vomiting among cancer patients: systematic review and meta-analysis.’ 
European Journal of Cancer Care, 17(5) pp. 431-443. 
 
Maddox, C., Laur, L. and Tian, L. (2009) ‘Antibacterial Activity of Phenolic Compounds 
Against the Phytopathogen Xylella fastidiosa.’ Current Microbiology, 60(1) pp. 53-58. 
 
 
 
Mahmoudi, S., Khali, M., Benkhaled, A., Benamirouche, K. and Baiti, I. (2016) ‘Phenolic 
and flavonoid contents, antioxidant and antimicrobial activities of leaf extracts from ten 
Algerian Ficus carica L. varieties.’ Asian Pacific Journal of Tropical Biomedicine, 6(3) pp. 
239-245. 
 
Mauritian Government. (1867) ‘A Collection of the Laws of Mauritius and Its 
Dependencies’ pp. 541. 
 
Mechoulam, R. and Shvo, Y. (1963) ‘The structure of cannabidiol.’ Tetrahedron, 19(12) pp. 
2073-2078. 
 
Mehmedic, Z., Radwan, M., Wanas, A., Khan, I., Cutler, S. and Elsohly, M. (2014) ‘In vitro 
binding affinity to human CB1 and CB2 receptors and antimicrobial activity of volatile oil 
from high potency Cannabis sativa.’ Planta Medica, 80(10). 
 
Mills, B., Yepes, A. and Nugent, K. (2015) ‘Synthetic Cannabinoids.’ The American Journal 
of Medical Sciences, 350(1) pp. 59-62.  
 
Naveed, M., Khan, T. A., Ali, I., Hassan, A., Ali, H., Din, Z. U., Hassan, Z., Tabassum, S., 
Saqib, Majid, A. and Ur Rehman, M. (2014) ‘In vitro antibacterial activity of Cannabis 
sativa leaf extracts to some selective pathogenic bacterial strains.’ International Journal 
of Biosciences, 4(4) pp. 65-70. 
 
Novak, J., Zitterl-Eglseer, K., Deans, S. G. and Franz, C. M. (2001) ‘Essential oils of different 
cultivars of Cannabis sativa L. and their antimicrobial activity.’ Flavour and Fragrance 
Journal, 16(4) pp. 259-262. 
 
Oh, E. and So, J. (2003) ‘A rapid method for RNA preparation from Gram-positive 
bacteria.’ Journal of Microbiological Methods, 52(3) pp. 395-398. 
 
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M. and Hall, W. (2002) 
‘Cannabis use and mental health in young people: cohort study.’ BMJ, 325(7374) pp. 
1195-1198. 
 
Pokrywka, M., Goralska, J. and Solnica, B. (2016) ‘Cannabinoids - a new weapon against 
cancer?’ Postȩpy higieny i medycyny doświadczalnej, 70(0) pp. 1309-1320. 
 
Polen, M. R., Sidney, S., Tekawa, I. S., Sadler, M and Friedman, G. D. (1993) ‘Health care 
use by frequent marijuana smokers who do not smoke tobacco.’ The Western Journal of 
Medicine, 158(6) pp. 596-601. 
 
 
 
Radwan, M. M., ElSohly, M. A., Slade, D., Ahmed, S. A., Khan, I. A. and Ross, S. A. (2009) 
‘Biologically Active Cannabinoids from High-Potency Cannabis sativa.’ Journal of Natural 
Products, 72(5) pp. 906-911. 
 
Richardson, J. F. and Reith, S. J. (1993) ‘Characterization of a strain of methicillin-resistant 
Staphylococcus aureus (EMRSA-15) by conventional and molecular methods.’ Journal of 
Hospital Infection, 25(1) pp. 45-52. 
 
Ross, S. A. & ElSohly, M. A. (1995) ‘Constituents of Cannabis sativa L. XXVIII. A review of 
the natural constituents: 1980–1994.’ Zagazig Journal of Pharmaceutical Science, 4(2) pp. 
1–10. 
 
Roth, M. D., Whittaker, K., Salehi, K., Tashkin, D. P. and Gayle, C. (2004) ‘Mechanisms for 
impaired effector function in alveolar macrophages from marijuana and cocaine 
smokers.’ Journal of Neuroimmunology, 147(2) pp. 82-86 
 
Ruben, J. E., Ball, K. R. and Chirino-Trejo, M. (2011) ‘Antimicrobial susceptibility of 
Staphylococcus aureus and Staphylococcus pseudointermedius isolated from various 
animals.’ The Canadian Veterinary Journal, 52(2) pp. 153-157. 
 
Russo, E. B. (2007) ‘History of Cannabis and its preparations in saga, science and 
sobriquet.’ Chemistry & Biodiversity.,4(8) pp. 2624–2648. 
 
Sarmadya, H., Solhi, H., Hajimir, T., Najarian-Araghi, N. and Chaznavi-Rad, E. (2013) 
‘Determination of the Antmicrobial Effects of Hydro-Alcoholic Extract of Cannabis sativa 
on Multiple Drug Resistant Bacteria Isolated from Nosocomial Infections.’ Iranian Journal 
of Toxicology, 7(23) 
 
Sirikantaramas, S., Morimoto, S., Shoyama, Y., Ishikawa, Y. Wada, Y., Shoyama, Y. and 
Taura, F. (2004) ‘The gene controlling marijuana psychoactivity: molecular cloning and 
heterologous expression of Delta1-tetrahydrocannabinolic acid synthase from Cannabis 
sativa L.’ The Journal of Biological Chemistry, 279(38) pp. 39767-39774. 
 
Taura, F., Sirikantaramas, S., Shoyama, Y., Shoyama, Y. & Morimoto, S. (2007) 
‘Phytocannabinoids in Cannabis sativa: Recent Studies on Biosynthetic Enzymes.’ 
Chemistry and Biodiversity, 4(8) pp. 1649-1663 
 
Turner, C. E. & ElSohly, M. A. (1981) ‘Biological activity of cannabichromene, its homologs 
and isomers.’ Journal of Clinical Pharmacology, 8 pp. 283-291. 
 
Van Klingeren, B. and Ten Ham, M. (1976) ‘Antibacterial activity of Δ9-
tetrahydrocannabinol and cannabidiol.’ Antonie van Leeuwenhoek, 42(1-2) pp. 9-12. 
 
 
 
Vu, T. T., Kim, H., Tran, V. K., Le Dang, Q., Nguyen, H. T.. Kim, H., Kim, I. S., Choi, G. J. and 
Kim, J. (2016) ‘In vitro antibacterial activity of selected medicinal plants traditionally used 
in Vietnam against human pathogenic bacteria.’ BMC Complementary and Alternative 
Medicine, 16(32). 
 
Wargent, E., Zaibi, M., Silvestri, C., Hislop, D., Stocker, C., Stott, C., Guy, G., Duncan, M., Di 
Marzo, V. and Cawthorne, M. (2013) ‘The cannabinoid Δ9-tetrahydrocannabivarin (THCV) 
ameliorates insulin sensitivity in two mouse models of obesity.’ Nutrition & Diabetes, 3(5) 
pp. 68-68. 
 
Wasim, K., Haq, I. and Ashraf, M. (1995) ‘Antimicrobial studies of the leaf of Cannabis 
sativa L.’ Pakistan Journal of Pharmaceutical Sciences, 8(1) pp. 29-38. 
 
Welling, M. T., Liu, L., Shapter, T., Raymond, C. A. and King, G. J. (2016) ‘Characterisation 
of cannabinoid composition in a diverse Cannabis sativa L. germplasm collection.’ 
Euphytica, 208 pp. 463-475. 
 
Wood, T. (1899) ‘Cannabinol, part I.’ Journal of Chemical Society, 75 pp. 20–36. 
 
Young, S. (2013) Marijuana stops child's severe seizures. CNN [Online] [Accessed on 20th 
February 2019] https://edition.cnn.com/2013/08/07/health/charlotte-child-medical-
marijuana/index.html  
 
Zalesky, A., Solowij, N., Yucel, M., Lubman, D., Takagi, M., Harding, I., Lorenzetti, V., 
Wang, R., Searle, K., Pantelis, C. and Seal, M. (2012) ‘Effect of long-term Cannabis use on 
axonal fibre connectivity.’ Brain, 135(7) pp. 2245-2255. 
 
Zengin, H. and Baysal, A. H. (2014) ‘Antibacterial and Antioxidant Activity of Essential Oil 
Terpenes against Pathogenic and Spoilage-Forming Bacteria and Cell Structure-Activity 
Relationships Evaluated by SEM Microscopy.’ Molecules, 19(11) pp. 17773-17798. 
 
 
